n-acetylneuraminic acid has been researched along with pci 32765 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Deng, Y; Hu, L; Li, C; Liu, M; Liu, X; Luo, X; Qiu, Q; Shi, T; Song, Y; Yan, X; Yang, S; Zhang, H; Zheng, H | 1 |
| Deng, Y; Fan, C; Gao, X; Li, C; Liu, X; Lu, S; Qiu, Q; Song, Y; Wang, S; Yan, X; Zhao, B | 1 |
2 other study(ies) available for n-acetylneuraminic acid and pci 32765
| Article | Year |
|---|---|
Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Topics: Adenine; Animals; Drug Delivery Systems; Immunotherapy; Macrophages; Male; Mice; N-Acetylneuraminic Acid; Nanoparticles; Neoplasms; Phosphatidylglycerols; Piperidines; Proton Magnetic Resonance Spectroscopy; Pyrazoles; Pyrimidines; Rats, Wistar; RAW 264.7 Cells; Stearic Acids | 2019 |
Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.
Topics: Animals; B7-H1 Antigen; Immunotherapy; Mice; N-Acetylneuraminic Acid; Neoplasm Recurrence, Local; Phospholipids; Tumor Microenvironment | 2023 |